Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

NATerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
DEVICE

Vortx Rx - Histotripsy BPH Device

Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.

Trial Locations (2)

43606

ProMedica Parkway Surgery Center, Toledo

48109

Univerisity of Michigan, Ann Arbor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HistoSonics, Inc.

INDUSTRY

NCT01896973 - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US) | Biotech Hunter | Biotech Hunter